Esmolol Use in Right Ventricular Dysfunction

Critical Contraindications and Warnings

• Patients with decompensated heart failure should avoid beta-blockers entirely, as recommended by the American Heart Association, due to the risk of worsening heart failure and cardiogenic shock 1, 2

Alternative Agents to Consider

• Non-dihydropyridine calcium channel blockers, such as diltiazem, should also be avoided in patients with decompensated heart failure, according to the American College of Cardiology, as they can worsen heart failure 1, 2
• Digoxin provides rate control with positive inotropic effects but has limited efficacy for acute conversion, as noted by the European Society of Cardiology 5, 2

Clinical Decision Algorithm

• If decompensated heart failure is present, esmolol is contraindicated, as stated by the American Heart Association, due to the high risk of worsening heart failure and cardiogenic shock 1, 2
• Electrical cardioversion should be considered first for hemodynamically unstable patients with tachyarrhythmia, as recommended by the American College of Cardiology 6

Monitoring Requirements

• Invasive arterial blood pressure monitoring is necessary for patients with RV dysfunction receiving esmolol, as recommended by the European Society of Cardiology, to closely monitor for hypotension and other adverse effects 3, 4

Key Considerations

• The American College of Cardiology recommends that patients with significant RV dysfunction should avoid esmolol due to the risk of worsening heart failure and cardiogenic shock 1, 2
• The European Society of Cardiology notes that esmolol can increase pulmonary vascular resistance, which can be catastrophic in patients with pulmonary hypertension 8